MedTrace Logo

HGG-TCP (High Grade Glioma - Tumor Concentrations of Protein Kinase Inhibitors)

NCT02239952 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2020-10-08

No results posted yet for this study

Summary

The purpose of this study is to determine intratumoral concentration of kinase inhibitors upon 2 weeks of treatment in tumor tissue (in the brain) of patients with high-grade gliomas (HGG).

Conditions

Interventions

DRUG

Sunitinib

50 mg once daily, oral use for 14 days

DRUG

vandetanib

300 mg, once daily, oral use for 14 days

DRUG

Erlotinib

150 mg, once daily, oral use for 14 days

Sponsors & Collaborators

  • Amsterdam UMC, location VUmc

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-11-30
Primary Completion
2021-11-30
Completion
2021-11-30

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02239952 on ClinicalTrials.gov